FBLG - FibroBiologics, Inc. Common Stock Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

FBLG

FIBROBIOLOGICS, INC. COMMON STOCK

NASDAQ

$1.81

▲ UP 2.84% (0.05)

KEY STATISTICS

Market Cap$3.79 M

52w High$12.40

52w Low$0.62

Dividend Yield—

Frequency—

P/E-0.32

Volume210.18K

Shares Out.2.10M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Peter O'Heeron

COMPENSATION 2026

Salary$617,500

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$39,864

Total$1,066,191

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 1, 2024

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$180.00

Target Low$180.00

Target Median$180.00

Target Consensus$180.00

UPCOMING EARNINGS

DateOct 30, 2026

DayFriday

Rev. Est.—

OCT

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-03-30	Reverse	1:20

PRICE

$1.81 ▲ UP 2.84% (+$0.05)

OVERLAYS

About FibroBiologics, Inc. Common Stock

https://www.fibrobiologics.com ↗

FibroBiologics, Inc., a Houston-based clinical-stage company, develops fibroblast-based therapies for degenerative disc disease, multiple sclerosis, wound healing, and early-stage research for autoimmune and cancer treatments.

INDUSTRY

Biotechnology

A PRODUCT FIBROBIOLOGICS, INC. COMMON STOCK IS KNOWN FOR

CYPS317

FibroBiologics is developing an allogeneic fibroblast spheroid therapy for moderate to severe psoriasis, with an IND filed to begin Phase 1/2 clinical trials, marking a key advancement in their inflammatory disease pipeline.